5 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie

2. TG Therapeutics, Inc. (NASDAQ: TGTX)

Maverick Capital’s Stake Value: $109,430,000
Percent of Maverick Capital’s 13F Portfolio: 1.02%
Number of Hedge Fund Holders: 28

TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company that focuses on the development of treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in phase 3 for the development of treatments for multiple sclerosis and chronic lymphocytic leukemia.

In Q2 2021, Maverick Capital has over 2.8 million shares in TG Therapeutics, Inc. (NASDAQ: TGTX), worth $109.4 million. The company represents 1.02% of the hedge fund’s 13F portfolio. Recently, Cantor Fitzgerald called TG Therapeutics, Inc. (NASDAQ: TGTX) ‘a buying opportunity’ which presents significant developments in the coming months. The firm keeps an ‘Overweight’ rating on TG Therapeutics, Inc. (NASDAQ: TGTX) with a $74 price target. The company expects its net revenue for 2022 and 2025 to be $50 million to $75 million. TG Therapeutics, Inc. (NASDAQ: TGTX) gained 13.1% in the past year.

Of the 873 hedge funds tracked by Insider Monkey, 28 funds have positions in TG Therapeutics, Inc. (NASDAQ: TGTX) in Q2 2021, up from 27 in the previous quarter. These stakes are valued at $553.4 million.